Status:
UNKNOWN
Search for Predictive Factors of Resistance to Treatment for Metastatic Castration-resistant Prostate Cancer by Studying the Expression of microRNAs
Lead Sponsor:
University Hospital, Tours
Conditions:
Prostate Cancer
Resistance, Disease
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
Several drugs are available for metastatic castration resistant prostate cancer such as chemotherapy (docetaxel, cabazitaxel) and novel hormonal agents (abiraterone, enzalutamide), in France. The onco...
Detailed Description
Several drugs are available for metastatic castration resistant prostate cancer such as chemotherapy (docetaxel, cabazitaxel) and novel hormonal agents (abiraterone, enzalutamide), in France. The onco...
Eligibility Criteria
Inclusion
- prostate adenocarcinoma
- metastatic disease, proven (CT or bone scintigraphy or MRI or positron emission tomography(PET)-CT or X ray)
- castration resistance, proven with biology or radiologic progression
- affiliated to a french social security regimen
Exclusion
- other cancer within five years
- any judiciary protection measure
Key Trial Info
Start Date :
June 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2023
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT04662996
Start Date
June 23 2021
End Date
November 30 2023
Last Update
November 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Tours
Tours, France, 37044